Every 10-Q that CNBX PHARMACEUTICAL INC (CNBX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CNBX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CNBX filings page.
CNBX Pharmaceuticals Inc. reported no revenue for the three and nine months ended May 31, 2026 and remains a pre-clinical oncology company focused on its RCC-33 colorectal cancer candidate. Operating expenses rose to $162,763 for the quarter and $299,728 for nine months, driving a nine‑month net loss of $311,982.
As of May 31, 2026, CNBX held only $9,487 in cash against current liabilities of $2,672,509 and a stockholders’ deficit of $2,659,714, and its auditors and management highlight substantial doubt about its ability to continue as a going concern. During the period, the company converted loans and interest of $148,561 into 921,805,889 common shares, increasing total shares outstanding to 1,475,768,095 and relying on repeated convertible and other promissory notes and forbearance agreements, including an extension on a senior secured note through September 30, 2026, to fund ongoing operations.
CNBX Pharmaceuticals Inc. reported no revenue for the three and six months ended February 28, 2026 and remained a pre-clinical oncology company focused on its RCC-33 colon cancer candidate. Quarterly operating expenses were $72,963, producing a net loss of $44,098, narrower than the prior-year quarter’s $69,788 loss.
For the six-month period, operating expenses rose to $136,965 and the net loss increased to $157,817 versus $104,140 a year earlier, mainly from higher general and administrative and salary costs. Financial income in the quarter reflected the impact of realizing convertible loans.
CNBX ended the period with only $12,154 in cash and total assets of $14,899, against current liabilities of $2,548,447, leaving a stockholders’ deficit of $(2,533,548). The company converted $120,562 of loans and interest into 571,805,889 new shares, increasing common shares outstanding to 1,225,768,095 as of April 14, 2026. Management and the auditors highlight substantial doubt about CNBX’s ability to continue as a going concern without additional financing.
CNBX Pharmaceuticals Inc. reported a larger quarterly loss and severe liquidity pressure for the three months ended November 30, 2025. The company generated no revenue and posted a net loss of $113,719, compared with $34,352 a year earlier, mainly from higher general and administrative expenses and increased interest on loans.
Cash and cash equivalents fell to $7,703, while current liabilities reached $2,584,133, leaving a stockholders’ deficit of $2,572,971. Management and the auditors highlight “substantial doubt” about the company’s ability to continue as a going concern, noting cumulative losses of $25,382,095 and the need for new financing.
To reduce debt, CNBX converted loans and interest totaling $37,041 into 199,234,460 new shares during the quarter, increasing shares outstanding to 753,196,666 at November 30, 2025. Subsequent conversions through early January 2026 added another 117,571,429 shares for $32,920 of debt, further diluting existing holders. The company also relies on forbearance agreements with an institutional investor on a senior secured note while it seeks additional capital.